{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:38:55Z","timestamp":1792132735379,"version":"4.4.0"},"reference-count":104,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019159","name":"The Martin Foundation","doi-asserted-by":"publisher","award":["RP124"],"award-info":[{"award-number":["RP124"]}],"id":[{"id":"10.13039\/100019159","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30DK120515"],"award-info":[{"award-number":["P30DK120515"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["5UL1TR001442"],"award-info":[{"award-number":["5UL1TR001442"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.xcrm.2026.103023","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:11:18Z","timestamp":1788534678000},"page":"103023","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1720-4355","authenticated-orcid":false,"given":"Federica","family":"Tavaglione","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.103023_bib1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra2412865","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"393","author":"Targher","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103023_bib2","doi-asserted-by":"crossref","DOI":"10.1172\/JCI186425","article-title":"Therapeutic horizons in metabolic dysfunction-associated steatohepatitis","volume":"135","author":"Newsome","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2026.103023_bib3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41572-025-00599-1","article-title":"Metabolic dysfunction-associated steatotic liver disease in adults","volume":"11","author":"Huang","year":"2025","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.xcrm.2026.103023_bib4","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41366-021-01015-w","article-title":"Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank","volume":"46","author":"De Vincentis","year":"2022","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.xcrm.2026.103023_bib5","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1038\/s41591-024-03283-1","article-title":"Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Raverdy","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.103023_bib6","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103023_bib7","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S2468-1253(25)00260-2","article-title":"Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis","volume":"11","author":"Li","year":"2026","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.xcrm.2026.103023_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155790","article-title":"Performance of non-invasive tests for liver fibrosis resolution after bariatric surgery","volume":"153","author":"Raverdy","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.xcrm.2026.103023_bib9","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103023_bib10","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1111\/apt.70196","article-title":"Review Article: GLP-1 Receptor Agonists and Glucagon\/GIP\/GLP-1 Receptor Dual or Triple Agonists-Mechanism of Action and Emerging Therapeutic Landscape in MASLD","volume":"61","author":"Zafer","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.xcrm.2026.103023_bib11","series-title":"FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease","year":"2024"},{"key":"10.1016\/j.xcrm.2026.103023_bib12","series-title":"FDA Approves Treatment for Serious Liver Disease Known as \u2018MASH\u2019","year":"2025"},{"key":"10.1016\/j.xcrm.2026.103023_bib13","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/gutjnl-2024-334023","article-title":"Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists","volume":"74","author":"Targher","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.xcrm.2026.103023_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70256","article-title":"Glucagon-Like Peptide-1 Receptor Agonists Improve MASH and Liver Fibrosis: A Meta-Analysis of Randomised Controlled Trials","volume":"45","author":"Mantovani","year":"2025","journal-title":"Liver Int."},{"key":"10.1016\/j.xcrm.2026.103023_bib15","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1097\/HEP.0000000000001254","article-title":"Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis","volume":"82","author":"Souza","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.xcrm.2026.103023_bib16","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41574-024-00979-9","article-title":"Targeting the incretin system in obesity and type 2 diabetes mellitus","volume":"20","author":"Ansari","year":"2024","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.xcrm.2026.103023_bib17","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jhep.2023.07.033","article-title":"Incretins (GLP-1 receptor agonists and dual\/triple agonists) and the liver","volume":"79","author":"Newsome","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.xcrm.2026.103023_bib18","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.xcrm.2026.103023_bib19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/jim-2017-000554","article-title":"Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option","volume":"66","author":"Dhir","year":"2018","journal-title":"J. Invest. Med."},{"key":"10.1016\/j.xcrm.2026.103023_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.103023_bib21","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.xcrm.2026.103023_bib22","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cmet.2026.02.018","article-title":"The many pathways driving liver inflammation in MASH","volume":"38","author":"Tilg","year":"2026","journal-title":"Cell Metab."},{"key":"10.1016\/j.xcrm.2026.103023_bib23","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1038\/s41591-025-03799-0","article-title":"Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"31","author":"Jara","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.103023_bib24","article-title":"Weight-dependent and independent effects of semaglutide in participants with MASH: Secondary analysis of the phase 3 ESSENCE trial","author":"Newsome","year":"2025","journal-title":"Oral presentation at AASLD 7\u201311"},{"key":"10.1016\/j.xcrm.2026.103023_bib25","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41575-025-01096-2","article-title":"Lessons from incretin-based therapy in MASH and obesity","volume":"22","author":"Tilg","year":"2025","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.xcrm.2026.103023_bib26","doi-asserted-by":"crossref","DOI":"10.1172\/JCI194751","article-title":"Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits","volume":"135","author":"Wong","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2026.103023_bib27","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC, Basic Transl. Sci."},{"key":"10.1016\/j.xcrm.2026.103023_bib28","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1139\/cjpp-2025-0148","article-title":"Anti-inflammatory properties of GLP-1 receptor agonists and other ancillary benefits from a pharmacological perspective","volume":"103","author":"Ros-Madrid","year":"2025","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.xcrm.2026.103023_bib29","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1196\/annals.1447.049","article-title":"Exendin-4 therapy in NOD mice with new-onset diabetes increases regulatory T cell frequency","volume":"1150","author":"Xue","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.xcrm.2026.103023_bib30","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.bbrc.2009.10.015","article-title":"Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression","volume":"390","author":"Kim Chung","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.xcrm.2026.103023_bib31","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.bbrc.2012.07.086","article-title":"Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation","volume":"425","author":"Shiraishi","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.xcrm.2026.103023_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097554","article-title":"Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism","volume":"9","author":"Krasner","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2026.103023_bib33","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cmet.2023.11.009","article-title":"Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation","volume":"36","author":"Wong","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.xcrm.2026.103023_bib34","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/cbf.3751","article-title":"Semaglutide (GLP-1 receptor agonist) stimulates browning on subcutaneous fat adipocytes and mitigates inflammation and endoplasmic reticulum stress in visceral fat adipocytes of obese mice","volume":"40","author":"Martins","year":"2022","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/j.xcrm.2026.103023_bib35","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s43587-025-01029-3","article-title":"Repurposing glucagon-like peptide-1 receptor agonists for the treatment of neurodegenerative disorders","volume":"6","author":"Sabbagh","year":"2025","journal-title":"Nat. Aging"},{"key":"10.1016\/j.xcrm.2026.103023_bib36","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/j.1476-5381.2012.01971.x","article-title":"Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders","volume":"166","author":"Salcedo","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.xcrm.2026.103023_bib37","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-024-01666-7","article-title":"evoke and evoke+: Two phase 3 randomised placebo-controlled trials of semaglutide in participants with early-stage Alzheimer\u2019s disease (NCT04777396 and NCT04777409)","volume":"17","author":"Cummings","year":"2025","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.xcrm.2026.103023_bib38","first-page":"3575","article-title":"Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide","volume":"85","author":"Deacon","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.xcrm.2026.103023_bib39","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.regpep.2007.02.006","article-title":"GIP receptor mRNA expression in different fat tissue depots in postmenopausal non-diabetic women","volume":"142","author":"Rudovich","year":"2007","journal-title":"Regul. Pept."},{"key":"10.1016\/j.xcrm.2026.103023_bib40","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1677\/joe.0.1300267","article-title":"Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36) amide, on fatty acid synthesis in explants of rat adipose tissue","volume":"130","author":"Oben","year":"1991","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.xcrm.2026.103023_bib41","doi-asserted-by":"crossref","first-page":"8557","DOI":"10.1074\/jbc.M609088200","article-title":"Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes. A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascade","volume":"282","author":"Kim","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2026.103023_bib42","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1172\/JCI110335","article-title":"Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs","volume":"68","author":"Wasada","year":"1981","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2026.103023_bib43","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.2337\/db10-0098","article-title":"Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans","volume":"59","author":"Asmar","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.xcrm.2026.103023_bib44","doi-asserted-by":"crossref","first-page":"E224","DOI":"10.1152\/ajpendo.00347.2016","article-title":"Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response","volume":"312","author":"Thondam","year":"2017","journal-title":"American Journal of Physiology-Endocrinology and Metabolism"},{"key":"10.1016\/j.xcrm.2026.103023_bib45","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/ijo.2013.73","article-title":"Glucose-dependent insulinotropic polypeptide has impaired effect on abdominal, subcutaneous adipose tissue metabolism in obese subjects","volume":"38","author":"Asmar","year":"2014","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.xcrm.2026.103023_bib46","doi-asserted-by":"crossref","DOI":"10.1038\/nutd.2016.15","article-title":"The blunted effect of glucose-dependent insulinotropic polypeptide in subcutaneous abdominal adipose tissue in obese subjects is partly reversed by weight loss","volume":"6","author":"Asmar","year":"2016","journal-title":"Nutr. Diabetes"},{"key":"10.1016\/j.xcrm.2026.103023_bib47","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1038\/ijo.2008.148","article-title":"Functional expression of glucose-dependent insulinotropic polypeptide receptors is coupled to differentiation in a human adipocyte model","volume":"32","author":"Weaver","year":"2008","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.xcrm.2026.103023_bib48","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1053\/j.gastro.2007.09.005","article-title":"Glucose-dependent insulinotropic polypeptide enhances adipocyte development and glucose uptake in part through Akt activation","volume":"133","author":"Song","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.xcrm.2026.103023_bib49","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How May GIP Enhance the Therapeutic Efficacy of GLP-1?","volume":"31","author":"Samms","year":"2020","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.xcrm.2026.103023_bib50","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.4049\/jimmunol.1401149","article-title":"Long-acting glucose-dependent insulinotropic polypeptide ameliorates obesity-induced adipose tissue inflammation","volume":"193","author":"Varol","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2026.103023_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.643144","article-title":"GIPR Signaling in Immune Cells Maintains Metabolically Beneficial Type 2 Immune Responses in the White Fat From Obese Mice","volume":"12","author":"Efimova","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2026.103023_bib52","doi-asserted-by":"crossref","DOI":"10.1093\/ejendo\/lvac004","article-title":"GIP reduces osteoclast activity and improves osteoblast survival in primary human bone cells","volume":"188","author":"Hansen","year":"2023","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.xcrm.2026.103023_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106058","article-title":"GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment","volume":"176","author":"Gabe","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.xcrm.2026.103023_bib54","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1210\/clinem\/dgae022","article-title":"Effects of Exogenous GIP and GLP-2 on Bone Turnover in Individuals With Type 2 Diabetes","volume":"109","author":"Skov-Jeppesen","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.xcrm.2026.103023_bib55","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaa097","article-title":"Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes","volume":"4","author":"Christensen","year":"2020","journal-title":"J. Endocr. Soc."},{"key":"10.1016\/j.xcrm.2026.103023_bib56","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12933-023-01940-2","article-title":"GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease","volume":"22","author":"Sachs","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.xcrm.2026.103023_bib57","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/s00125-017-4354-8","article-title":"GLP-1\/glucagon receptor co-agonism for treatment of obesity","volume":"60","author":"S\u00e1nchez-Garrido","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.xcrm.2026.103023_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2016.6","article-title":"Pancreatic regulation of glucose homeostasis","volume":"48","author":"R\u00f6der","year":"2016","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.xcrm.2026.103023_bib59","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0021-9258(18)64236-X","article-title":"Effect of glucagon on the metabolism of adipose tissue","volume":"236","author":"HAGEN","year":"1961","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2026.103023_bib60","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0022-2275(20)40346-3","article-title":"Effect of hormones on lipolysis and esterification of free fatty acids during incubation of adipose tissue in vitro","volume":"4","author":"VAUGHAN","year":"1963","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.xcrm.2026.103023_bib61","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0022-2275(20)39429-3","article-title":"Selective loss of adipose cell responsiveness to glucagon with growth in the rat","volume":"13","author":"Manganiello","year":"1972","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.xcrm.2026.103023_bib62","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0022-2275(20)36828-0","article-title":"Studies of glucagon resistance in large rat adipocytes: 125I-labeled glucagon binding and lipolytic capacity","volume":"15","author":"Livingston","year":"1974","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.xcrm.2026.103023_bib63","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1210\/endo-113-1-270","article-title":"Studies of the biological effect and degradation of glucagon in the rat perifused isolated adipose cell","volume":"113","author":"Heckemeyer","year":"1983","journal-title":"Endocrinology"},{"key":"10.1016\/j.xcrm.2026.103023_bib64","first-page":"2085","article-title":"Physiological levels of glucagon do not influence lipolysis in abdominal adipose tissue as assessed by microdialysis","volume":"86","author":"Gravholt","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.xcrm.2026.103023_bib65","first-page":"1229","article-title":"Action of glucagon and glucagon-like peptide-1-(7-36) amide on lipolysis in human subcutaneous adipose tissue and skeletal muscle in vivo","volume":"86","author":"Bertin","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.xcrm.2026.103023_bib66","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1210\/er.2018-00117","article-title":"Targeting the Incretin\/Glucagon System With Triagonists to Treat Diabetes","volume":"39","author":"Capozzi","year":"2018","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.xcrm.2026.103023_bib67","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13372","article-title":"The incretin\/glucagon system as a target for pharmacotherapy of obesity","volume":"23","author":"Del Prato","year":"2022","journal-title":"Obes. Rev."},{"key":"10.1016\/j.xcrm.2026.103023_bib68","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103023_bib69","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.103023_bib70","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103023_bib71","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103023_bib72","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.xcrm.2026.103023_bib73","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103023_bib74","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1016\/S0140-6736(25)02114-2","article-title":"Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study","volume":"406","author":"Noureddin","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.103023_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101633","article-title":"BI 456906: Discovery and preclinical pharmacology of a novel GCGR\/GLP-1R dual agonist with robust anti-obesity efficacy","volume":"66","author":"Zimmermann","year":"2022","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.xcrm.2026.103023_bib76","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.cmet.2024.03.011","article-title":"New and emerging treatments for metabolic dysfunction-associated steatohepatitis","volume":"36","author":"Tincopa","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.xcrm.2026.103023_bib77","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.16583","article-title":"Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH","volume":"54","author":"Majzoub","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.xcrm.2026.103023_bib78","doi-asserted-by":"crossref","first-page":"518","DOI":"10.21037\/hbsn-2021-13","article-title":"Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic steatohepatitis: new insights from subcutaneous semaglutide","volume":"10","author":"Mantovani","year":"2021","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"10.1016\/j.xcrm.2026.103023_bib79","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/apt.16608","article-title":"Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging","volume":"54","author":"Flint","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.xcrm.2026.103023_bib80","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.cgh.2024.04.017","article-title":"Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis","volume":"22","author":"Shankar","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.xcrm.2026.103023_bib81","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease","volume":"79","author":"Romero-G\u00f3mez","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.xcrm.2026.103023_bib82","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.xcrm.2026.103023_bib83","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.103023_bib84","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/dmrr.2561","article-title":"Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes","volume":"30","author":"Shao","year":"2014","journal-title":"Diabetes. Metab. Res. Rev."},{"key":"10.1016\/j.xcrm.2026.103023_bib85","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)","volume":"63","author":"Kuchay","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.xcrm.2026.103023_bib86","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/ndt\/gfaf193","article-title":"The effect of GLP-1 receptor agonists on renal outcomes: a systematic review and meta-analysis","volume":"41","author":"Sasaki","year":"2026","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.xcrm.2026.103023_bib87","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1161\/CIRCULATIONAHA.124.071689","article-title":"Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis","volume":"150","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.xcrm.2026.103023_bib88","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.jacc.2025.08.027","article-title":"Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients","volume":"86","author":"Galli","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.xcrm.2026.103023_bib89","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.103023_bib90","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12986-024-00871-3","article-title":"Diverting hepatic lipid fluxes with lifestyles revision and pharmacological interventions as a strategy to tackle steatotic liver disease (SLD) and hepatocellular carcinoma (HCC)","volume":"21","author":"Misceo","year":"2024","journal-title":"Nutr. Metab."},{"key":"10.1016\/j.xcrm.2026.103023_bib91","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3787","article-title":"Non-invasive assessment of hepatic steatosis by ultrasound-derived fat fraction in individuals at high-risk for metabolic dysfunction-associated steatotic liver disease","volume":"40","author":"Tavaglione","year":"2024","journal-title":"Diabetes. Metab. Res. Rev."},{"key":"10.1016\/j.xcrm.2026.103023_bib92","doi-asserted-by":"crossref","DOI":"10.1172\/JCI198334","article-title":"The pathogenesis of hepatic steatosis in MASLD: a lipid droplet perspective","volume":"135","author":"Krahmer","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2026.103023_bib93","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/liv.13972","article-title":"Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease","volume":"39","author":"Pelusi","year":"2019","journal-title":"Liver Int."},{"key":"10.1016\/j.xcrm.2026.103023_bib94","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.xcrm.2026.103023_bib95","article-title":"Signaling pathways that activate hepatic stellate cells during liver fibrosis","volume":"11","author":"Zhang","year":"2024","journal-title":"Front. Med."},{"key":"10.1016\/j.xcrm.2026.103023_bib96","doi-asserted-by":"crossref","first-page":"9671","DOI":"10.3390\/ijms24119671","article-title":"Liver Fibrosis Resolution: From Molecular Mechanisms to Therapeutic Opportunities","volume":"24","author":"Pei","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2026.103023_bib97","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression","volume":"18","author":"Kisseleva","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.xcrm.2026.103023_bib98","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/dom.14551","article-title":"Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss","volume":"24","author":"Wharton","year":"2022","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.xcrm.2026.103023_bib99","first-page":"339","article-title":"Qualitative exploration of factors influencing the plan selection process by Medicare beneficiaries","volume":"27","author":"Zhao","year":"2021","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.xcrm.2026.103023_bib100","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/s41574-025-01160-6","article-title":"Balancing weight and muscle loss in GLP1 receptor agonist therapy","volume":"21","author":"Sanchis-Gomar","year":"2025","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.xcrm.2026.103023_bib101","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.xcrm.2026.103023_bib102","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/liv.14758","article-title":"Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension","volume":"41","author":"Paternostro","year":"2021","journal-title":"Liver Int."},{"key":"10.1016\/j.xcrm.2026.103023_bib103","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41574-025-01197-7","article-title":"Sarcopenia and MASLD: novel insights and the future","volume":"22","author":"Liu","year":"2026","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.xcrm.2026.103023_bib104","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1016\/j.jhep.2021.01.025","article-title":"Sarcopenia and frailty in decompensated cirrhosis","volume":"75","author":"Tandon","year":"2021","journal-title":"J. Hepatol."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126004404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126004404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:47:52Z","timestamp":1789591672000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126004404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":104,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2666379126004404"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.103023","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.103023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103023"}}